Expert Opinion on Therapeutic Patents

Papers
(The H4-Index of Expert Opinion on Therapeutic Patents is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
The role of patent analysis in target selection74
FAK inhibitors in cancer, a patent review – an update on progress38
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)34
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)32
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities32
Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present)32
Update on mGlu4 modulator patents: 2017 to present27
T-type calcium channel blockers: a review of recent advances (2018–2025)26
Recent developments of agents targeting Vibrio cholerae : patents and literature data26
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)26
Caspase inhibitors: a review on recently patented compounds (2016–2023)25
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present25
An updated patent review of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors (2020–present)25
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)23
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
An updated patent review of AKT inhibitors (2020 – present)22
A patent review of MAPK inhibitors (2018 – present)20
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review20
Inhibition of GTPase KRAS G12D : a review of patent literature19
0.83377003669739